LAWRENCE, Mass., June 29, 2011 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced that it has entered into a new 11-year lease agreement with 350 Riverwalk LLC to move its corporate headquarters to the revitalized historic mill complex on the River Walk Campus at 350 Merrimack Street, Lawrence, MA. The move, which is expected to be completed in mid-2012, reaffirms NxStage's over ten year commitment to Lawrence, MA and the Greater Merrimack Valley community since 2001.
(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )
The revitalized mill space is in a more central location and is expected to allow the Company's customers, partners and employees easier access to the office and many local amenities.
"We've built a unique and innovative culture at NxStage," said Jeffrey Burbank, Chief Executive Officer, NxStage Medical, Inc. "We've had a great experience in Lawrence and we're proud to contribute to the area's growth and vitality."
"NxStage Medical has been a welcome employer and corporate citizen in the Fifth District, and their decision to stay and grow in Lawrence will continue to benefit the economic development and revitalization of the City," said Congresswoman Niki Tsongas (D-MA). "Given the importance of the medical technology industry to Massachusetts, innovative employers like NxStage help to ensure the presence of good jobs in our community and I wish them continued success in the years ahead."
"NxStage's move to the revitalized Riverwalk Properties is one of the most exciting additions to our complex to date," said Sal Lupoli, President/CEO of 350 Riverwalk LLC. "I am extremely proud NxStage will be joining our complex."
Located in the heart of the Merrimack Valley, the Riverwalk Properties consists of five separate buildings creating a unique campus style business environment. The campus features easy access to public transportation and a friendly, collaborative and professional environment. Riverwalk Properties has a diverse group of corporate tenants, a number of which are in the health care industry.
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
SOURCE NxStage Medical, Inc.